within Pharmacolibrary.Drugs.ATC.A;

model A07EA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.04,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A07EA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tixocortol is a corticosteroid drug used primarily for its anti-inflammatory properties. It has been utilized in the treatment of local inflammatory conditions of the oral cavity, throat, and gastrointestinal tract, especially in cases where systemic corticosteroid effects should be avoided. Its use today is limited, primarily reserved for specific local applications due to the development of newer corticosteroids.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data was found for tixocortol in humans. Estimates are provided based on corticosteroid class properties, assuming standard adult with normal renal and hepatic function.</p><h4>References</h4><ol><li><p>Ardizzone, S, &amp; Bianchi Porro, G (2002). Comparative tolerability of therapies for ulcerative colitis. <i>Drug safety</i> 25(8) 561–582. DOI:<a href=\"https://doi.org/10.2165/00002018-200225080-00003\">10.2165/00002018-200225080-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12113642/\">https://pubmed.ncbi.nlm.nih.gov/12113642</a></p></li><li><p>Chanoine, F, et al., &amp; Junien, JL (1987). Isolation and identification of major metabolites of tixocortol pivalate in human urine. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 15(6) 868–876. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2893715/\">https://pubmed.ncbi.nlm.nih.gov/2893715</a></p></li><li><p>Linn, FV, &amp; Peppercorn, MA (1992). Drug therapy for inflammatory bowel disease: Part I. <i>American journal of surgery</i> 164(1) 85–89. DOI:<a href=\"https://doi.org/10.1016/s0002-9610(05)80654-3\">10.1016/s0002-9610(05)80654-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1626611/\">https://pubmed.ncbi.nlm.nih.gov/1626611</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A07EA05;
